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Objectives
Systematically build a robust semi-automated closed CAR-
T manufacturing process that can be widely adopted by the
T-cell immunotherapy industry:
 Identify and apply commercially available reagents that
enhance process efficiency
 Integrate automation strategies to reduce manual and
open operations
 Maintain flexibility to concurrently manufacture CAR-T
products
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Immunotherapy has generated excitement as what many
are calling the "fifth pillar" of cancer treatment. Among the
several types of therapies, CAR-T cells have shown
impressive therapeutic efficacy, especially in advanced
blood cancers. With the recent approval of Kymriah™ and
Yescarta™, CAR-T cells continue to be the focus of a
growing clinical trial pipeline. However, there are remain
challenges associated with routinely offering these products
as treatment alternatives, including a costly manufacturing
process that relies on a lengthy and complex open workflow
with manual manipulations that lead to product variability. To
address these challenges, we have investigated individual
CAR-T unit operations to identify commercially available
reagents and modular equipment to drive process closure
and automation that will improve workflow efficiency and
product consistency.
Conclusions
Developed a semi-automated closed CAR-T manufacturing
process that can be widely adopted by the T-cell
immunotherapy industry:
 1E10 GFP transduced T-cells in an 8 day process, n=2
donors
 Identified EasySepTM as a commercially available reagent
to enhance process efficiency
 Integrated the the Smart-Max, SepaxTM C-Pro, XuriTM
W25 bioreactor, SefiaTM and VIA FreezeTMas automation
strategies to reduce manual and open operations
Results
Future Work
 Development of an isolation process with closed a
EasySep™ platform
 CAR-T manufacturing runs with transduction, expansion
and harvest
 CAR-T manufacturing runs with patient material
 Further optimization of T-cell bioreactor expansion
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Identifying an Early Closed Culture Alternative
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Figure 1: T-cell selection comparison between positive selection
and negative depletion (n=3 donors). (A) FlowJo™ representation of
gated cells on day 0 after EasySepTM isolation. (B) CD3+ T-cell recovery
was highest with the EasySepTM (>62%). Higher T-cell purity observed
in the two CD3+ selection methods. Greater than 92% viability after
being expanded 5 days. Comparable expansion rates across donors.
Figure 2: Effect of T-cell selection and day of infection on transduction efficiency (n=3 donors). (A)
Higher transduction efficiency in CD3+ selected cells. Day 1 infection generated highest transduction
efficiency. (B) Day 7 T-cells transduced with GFP.
Figure 3: Comparing shake flasks
(SF) to T-Flasks (n=3 donors).
Shake flask platform offers similar
expansion profile to T-Flasks. T-cell
phenotype and viability not
compromised in SF.
Figure 4: Comparing ACTd to T-Flasks, SF, and retronectin (RN) coated plates (n=2 donors).
Highest transduction efficiencies achieved using ACTd method in two donors (>74% transduction
efficiency using ACTd) with >87% viability maintained post-ACTd.
Figure 5: Simulated CAR-T transduction and expansion using GFP (n=2 donors). (A) T-cell
expansion and viability. ~1E10 transduced T-cells on Day 8 (starting with 2E8 T-cells). (B) T-cell
transduction efficiency. >80% transduced T-cells on Day 8 of process. (C) FlowJoTM representation of
gated cells on Day 8.
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